According to Zhitong Finance App News, Baili Tianheng (688506.SH) announced that the world's first, new concept, and currently the world's first and only EGFR×HER3 dual antibody ADC drug “Renkang elontuzumab” (iza-bren) for injection, which was independently developed by Chengdu Bailidot Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, passed national health insurance negotiations in the first year of marketing and was successfully included in the “National Health Insurance Catalogue (2026 Edition)”. The scope of payment for this drug is limited to adult patients with relapsed/metastatic nasopharyngeal cancer who have previously been treated with at least second-line systemic chemotherapy (and PD-1/PD-L1 inhibitors).

Zhitongcaijing · 2d ago
According to Zhitong Finance App News, Baili Tianheng (688506.SH) announced that the world's first, new concept, and currently the world's first and only EGFR×HER3 dual antibody ADC drug “Renkang elontuzumab” (iza-bren) for injection, which was independently developed by Chengdu Bailidot Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, passed national health insurance negotiations in the first year of marketing and was successfully included in the “National Health Insurance Catalogue (2026 Edition)”. The scope of payment for this drug is limited to adult patients with recurrent/metastatic nasopharyngeal cancer who have previously undergone at least second-line systemic chemotherapy (and who have used PD-1/PD-L1 inhibitors).